NEW YORK, Nov. 3, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will host its earnings call on Thursday, November 10, 2022, at 8:30 a.m. EDT to discuss its financial results for the quarter ended September 30, 2022 and provide a business update.
Individuals may participate via telephone by dialing (888) 999-3182 (domestic) or (848) 280-6330 (international) and using conference ID 8072033. The webcast can be accessed live here or on MindMed's Investor Resources webpage. The webcast will be archived on the company's website for at least 30 days after the conference call.
MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.
MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
For Media: firstname.lastname@example.org
For Investors: email@example.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/mindmed-to-host-earnings-call-to-discuss-third-quarter-2022-financial-results-and-provide-business-update-301667385.html
SOURCE Mind Medicine (MindMed) Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2022/03/c4946.html
The work included in this article is based on current events, technical charts, company news releases, and the author’s opinions. It may contain errors, and you shouldn’t make any investment decision based solely on what you read here. This publication contains forward-looking statements, including but not limited to comments regarding predictions and projections. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. This publication is provided for informational and entertainment purposes only and is not a recommendation to buy or sell any security. Always thoroughly do your own due diligence and talk to a licensed investment adviser prior to making any investment decisions. Junior resource and biotechnology companies can easily lose 100% of their value so read company profiles on www.SEDAR.com for important risk disclosures. It’s your money and your responsibility.